병기별 만성 골수성 백혈병(CML) 치료 시장 : 치료법별, 병기별, 치료 환경별, 환자 연령층별 - 세계 예측(2026-2032년)

The Treating Chronic Myeloid Leukemia by Phase Market was valued at USD 4.92 billion in 2025 and is projected to grow to USD 5.26 billion in 2026, with a CAGR of 7.33%, reaching USD 8.08 billion by 2032.

A strategic introduction to the clinical pathways, therapeutic evolution, and stakeholder imperatives shaping phase-specific treatment of chronic myeloid leukemia

Chronic myeloid leukemia presents a distinctive clinical pathway characterized by discrete phases-chronic phase, accelerated phase, and blast crisis-each demanding a calibrated therapeutic approach. Over the past two decades, the therapeutic backbone has shifted from non-specific cytotoxic therapies and allogeneic hematopoietic stem cell transplantation toward targeted small molecules that inhibit the BCR-ABL kinase. This evolution reshaped treatment goals from merely extending survival to achieving deep molecular responses, improving quality of life, and enabling treatment-free remission in selected patients.

Clinicians and health system leaders must now navigate a more complex landscape where therapeutic selection depends on prior treatment history, mutational profile, comorbidity burden, and patient preferences. Meanwhile, regulatory frameworks and payer expectations increasingly emphasize real-world evidence and value-based outcomes, prompting manufacturers and providers to align around measurable clinical endpoints. As a result, multidisciplinary decision making-integrating hematology, transplant services, pharmacoeconomics, and patient support programs-has become essential to optimize individual patient journeys and broader service delivery.

Transitioning from historical practice to contemporary standards requires a granular understanding of the drivers of treatment choice across disease phases, the operational implications for treatment settings, and the strategic levers available to stakeholders seeking to improve outcomes while containing costs. This introduction frames the deeper analyses that follow, providing context for the clinical, commercial, and policy trends shaping care for people living with chronic myeloid leukemia.

How molecular advances, regulatory evolution, and care delivery transformation are redefining clinical practice and commercial strategies across chronic myeloid leukemia care

The therapeutic landscape for chronic myeloid leukemia is experiencing transformative shifts driven by advances in molecular science, regulatory innovations, and evolving care delivery models. Precision targeting of the BCR-ABL fusion protein through successive generations of tyrosine kinase inhibitors set a precedent for iterative drug development that now informs strategies across hematologic malignancies. Concurrently, improvements in molecular monitoring techniques and standardized response criteria have enabled clinicians to make earlier, individualized treatment decisions and to consider treatment discontinuation in carefully selected patients.

From a commercial perspective, competition among oral targeted agents has reoriented market dynamics toward differentiated safety profiles, dosing convenience, and long-term tolerability. This has triggered a downstream focus on adherence programs, digital therapeutics, and patient support services that bolster sustained molecular response. At the same time, regulatory agencies are increasingly open to adaptive approval pathways and label expansions based on surrogate markers, encouraging sponsors to generate robust translational and real-world evidence to support broader indications.

Importantly, care delivery is also shifting. Specialty clinics and outpatient infusion centers are expanding their role, enabling more decentralized management of chronic phase disease and reducing reliance on inpatient resources. These shifts create both opportunities and responsibilities for payers, providers, and industry actors to harmonize access strategies, optimize resource allocation, and ensure that innovation translates into measurable improvements in survival and quality of life across diverse patient populations.

Assessment of how new trade measures and import costs are reshaping supply chains, clinical operations, and patient access pathways for leukemia therapies

The imposition of new tariff measures by the United States in two thousand twenty-five has rippled through pharmaceutical supply chains and commercial operations in ways that affect access, cost structures, and strategic sourcing decisions for chronic myeloid leukemia therapies. Active pharmaceutical ingredients, finished dose formulations, and specialized manufacturing equipment often cross multiple borders during production; tariffs that increase import costs can therefore raise the landed cost of drugs and raw materials, prompting manufacturers to reassess production footprints. In response, some sponsors are accelerating plans to localize manufacturing or to diversify suppliers across jurisdictions less affected by trade measures.

Clinical programs and trial operations also feel the impact. Tariffs that increase the cost of investigational products or required devices can influence trial budgeting and site selection, and may complicate multinational supply logistics for phase-specific studies. Moreover, payer negotiations in the United States and in markets closely linked to its trade policy become more complex when baseline cost assumptions shift, which in turn affects formulary placement and patient access programs. Health systems and specialty clinics that manage long-term oral targeted therapies may face higher procurement expenditures, compelling pharmacy and procurement teams to renegotiate contracts and seek alternative sourcing strategies.

Policymakers, regulators, and industry actors are pursuing mitigation tactics. These include expanding bilateral manufacturing agreements, investing in regional API hubs, and leveraging tariff exemption processes where available. In parallel, manufacturers are enhancing transparency around unit costs and total cost of care to strengthen value arguments during reimbursement discussions. Clinicians and health system leaders should anticipate and plan for evolving supply chain contingencies, ensuring that contingency buffers, alternative sourcing pathways, and stakeholder communication plans are in place to preserve continuity of care through each disease phase.

Critical segmentation insights illustrating how therapeutic class, disease phase, treatment setting, and age cohorts interact to determine care pathways and outcomes

Segment-level dynamics reveal how treatment choice, disease phase, care setting, and patient age together shape clinical decision making and service design across chronic myeloid leukemia. Analysis by treatment type underscores the centrality of tyrosine kinase inhibitors relative to chemotherapy and hematopoietic stem cell transplantation, with first generation agents establishing disease control and later generations addressing resistance and tolerability. Within the tyrosine kinase inhibitor family, first generation agents remain important for initial disease control, while second generation agents such as bosutinib, dasatinib, and nilotinib are frequently utilized to manage intolerance or resistance and to achieve deeper molecular responses in selected patients. Third generation agents provide targeted options for complex mutational profiles and for patients who have progressed after earlier lines of therapy.

When viewed by disease phase, chronic phase management emphasizes long-term oral therapy and monitoring to sustain deep molecular responses and consider treatment-free remission strategies, whereas accelerated phase and blast crisis require more aggressive, often combination-based approaches and rapid escalation to transplant where appropriate. Treatment setting further modulates pathways: hospital inpatient units manage acute complications and intensive therapies; hospital outpatient clinics deliver infusions, monitoring, and complex procedural care; and specialty clinics provide longitudinal management for oral targeted therapies alongside adherence and monitoring programs. Patient age groups introduce additional complexity, as pediatric patients require dosing and psychosocial adaptations, geriatric patients present comorbidity and frailty considerations that influence tolerability, and adults represent the largest heterogeneous cohort with varying comorbidity profiles and life-stage priorities.

Together, these segmentation lenses highlight the need for integrated care pathways that align therapeutic choice to disease biology, treatment setting, and patient-specific factors, supporting optimized outcomes across phases of disease progression.

How diverse regional healthcare infrastructures, regulatory frameworks, and procurement practices shape therapy adoption and patient access globally

Regional dynamics exert a profound influence on access, care delivery models, and the adoption of novel therapies for chronic myeloid leukemia. In the Americas, systems with advanced outpatient infrastructures and strong specialty pharmacy networks support broad adoption of oral targeted therapies, yet disparities in access persist across payer types and rural versus urban settings. European markets, the Middle East, and Africa display marked heterogeneity: several European health systems integrate robust molecular monitoring and national treatment protocols that facilitate guideline-concordant care, while parts of the Middle East and Africa face infrastructure and resource constraints that limit access to later-generation agents and advanced monitoring capabilities. The Asia-Pacific region combines high-volume treatment centers and rapidly evolving local manufacturing capacity with significant variability in regulatory pathways and reimbursement environments, contributing to differentiated adoption curves for newer agents and care models.

These geographic distinctions affect everything from the pacing of clinical adoption to supply chain design. Market entrants and established manufacturers must therefore tailor strategies to regional payer expectations, local diagnostic capacity, and distribution channels. Clinics and hospital systems should align molecular monitoring protocols and telehealth-enabled follow-up approaches to regional patient needs, considering the variable availability of hematopoietic stem cell transplantation services and the differing prevalence of comorbid conditions that influence treatment tolerability. Cross-regional collaborations and knowledge sharing can accelerate best practice diffusion, but successful translation requires attention to local regulatory and operational realities.

Strategic corporate behaviors, collaborative models, and operational priorities driving innovation, supply resilience, and patient support in leukemia care

Corporate strategies among leading developers and service providers influence the trajectory of therapeutic innovation and access in chronic myeloid leukemia. Pharmaceutical innovators continue to invest in next-generation kinase inhibitors aiming to improve potency against resistant clones while reducing off-target toxicity and fostering adherence. Partnerships between drug developers, diagnostics firms, and academic centers are increasingly common, enabling integrated approaches to mutation-driven therapy selection and streamlined clinical development. Contract research organizations and specialized clinical networks play a pivotal role in running phase-specific studies, particularly those targeting accelerated phase and blast crisis populations where enrollment is more challenging.

In parallel, manufacturers and health systems are developing comprehensive patient support ecosystems encompassing molecular monitoring, adherence support, and financial navigation to maximize real-world effectiveness of oral targeted therapies. Supply chain resilience has become a strategic priority, prompting investments in geographic diversification of manufacturing and in digital supply chain visibility tools. Additionally, smaller biotech firms and academic spinouts continue to explore complementary modalities, including immunotherapeutic approaches and combination regimens that may alter future standard-of-care algorithms. Collectively, these corporate actions emphasize collaboration across the value chain to address unmet needs, reduce time to diagnosis and appropriate therapy selection, and improve longitudinal outcomes across disease phases.

Actionable recommendations for manufacturers, providers, and payers to enhance outcomes, secure supply, and align evidence generation with value-based care expectations

Industry leaders can take a series of pragmatic actions to strengthen clinical outcomes, secure supply continuity, and accelerate value delivery across chronic myeloid leukemia care. First, invest in integrated monitoring and adherence programs that combine molecular testing, digital engagement, and coordinated case management to support durable responses and enable appropriate consideration of treatment discontinuation where clinically justified. Second, prioritize supply chain diversification and regional manufacturing partnerships that reduce exposure to single-source risks and tariff-driven cost volatility while maintaining quality and regulatory compliance.

Third, align evidence generation with payer needs by embedding pragmatic real-world data collection into post-authorization safety studies and registries, thereby demonstrating value across diverse patient populations and care settings. Fourth, cultivate collaborative research partnerships with academic centers and specialty clinics to accelerate enrollment in phase-specific trials for accelerated phase and blast crisis patients, where unmet need remains highest. Fifth, tailor commercial and access strategies to regional realities, acknowledging differences in diagnostic infrastructure, reimbursement models, and patient support requirements. Finally, engage proactively with policymakers and payers to design value-based contracting models that reflect long-term outcomes and total cost of care, ensuring that innovative therapies deliver measurable benefit while remaining sustainable for healthcare systems.

Methodology that integrates clinical evidence, regulatory review, expert interviews, and supply chain scenario analysis to synthesize actionable, phase-specific insights

This research synthesis relies on a multidisciplinary methodology that integrates peer-reviewed clinical literature, regulatory guidance documents, public health data, expert interviews, and operational best practices to produce a comprehensive view of treatment patterns and strategic implications. Clinical evidence was reviewed with an emphasis on randomized controlled trials, long-term observational studies, and guideline updates that inform standard-of-care decisions across disease phases. Regulatory and policy materials were analyzed to extract trends in approval pathways, label expansions, and reimbursement criteria that alter commercial and access planning.

To contextualize commercial and operational factors, the methodology incorporated structured interviews with hematologists, transplant specialists, specialty pharmacists, and health system procurement leaders, supplementing literature findings with real-world practice insight. Supply chain and tariff impacts were assessed through scenario analysis encompassing cross-border manufacturing flows, procurement contracts, and logistics considerations. Finally, triangulation across data streams ensured that recommendations and insights reflect both empirical evidence and frontline operational experience, producing pragmatic guidance for stakeholders seeking to optimize phase-specific care delivery and strategic planning.

Synthesis of clinical, operational, and policy imperatives that stakeholders must integrate to advance outcomes and sustain access across all phases of disease

In conclusion, the treatment of chronic myeloid leukemia has evolved into a nuanced discipline where therapeutic selection, monitoring intensity, and care setting must be tightly aligned with disease phase, patient characteristics, and regional infrastructure. Advances in molecular targeting and monitoring have transformed expectations around deep and durable responses, while commercial and policy trends increasingly demand measurable value and robust real-world evidence. Trade and supply chain dynamics, including tariff shifts, further complicate the operational landscape and underscore the importance of resilience and strategic sourcing.

Moving forward, stakeholders who succeed will be those that integrate clinical excellence with agile operational strategies: investing in molecular diagnostics and adherence infrastructure, diversifying manufacturing and supply chains, and partnering across the ecosystem to generate the evidence payers require. By adopting these approaches, clinicians, manufacturers, and health systems can improve outcomes across chronic, accelerated, and blast phases of disease, while ensuring that innovation translates into accessible and sustainable care delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Type

• 8.1. Chemotherapy
• 8.2. Stem Cell Transplantation
• 8.3. Tyrosine Kinase Inhibitor
  • 8.3.1. First Generation TKI
  • 8.3.2. Second Generation TKI
    • 8.3.2.1. Bosutinib
    • 8.3.2.2. Dasatinib
    • 8.3.2.3. Nilotinib
  • 8.3.3. Third Generation TKI

9. Treating Chronic Myeloid Leukemia by Phase Market, by Phase

• 9.1. Accelerated Phase
• 9.2. Blast Crisis
• 9.3. Chronic Phase

10. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Setting

• 10.1. Hospital Inpatient
• 10.2. Hospital Outpatient
• 10.3. Specialty Clinic

11. Treating Chronic Myeloid Leukemia by Phase Market, by Patient Age Group

• 11.1. Adult
• 11.2. Geriatric
• 11.3. Pediatric

12. Treating Chronic Myeloid Leukemia by Phase Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Treating Chronic Myeloid Leukemia by Phase Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Treating Chronic Myeloid Leukemia by Phase Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Treating Chronic Myeloid Leukemia by Phase Market

16. China Treating Chronic Myeloid Leukemia by Phase Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. AbbVie Inc.
• 17.6. AstraZeneca PLC
• 17.7. Biogen Inc.
• 17.8. Bristol-Myers Squibb Company
• 17.9. Celgene Corporation by Bristol Myers Squibb Company
• 17.10. Cipla Limited
• 17.11. Dr. Reddy's Laboratories Limited
• 17.12. Eisai Co., Ltd.
• 17.13. F. Hoffmann-La Roche Ltd.
• 17.14. Gilead Sciences, Inc.
• 17.15. GlaxoSmithKline PLC
• 17.16. Incyte Corporation
• 17.17. Intas Pharmaceuticals Limited
• 17.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
• 17.19. Merck KGaA
• 17.20. Novartis AG
• 17.21. Pfizer Inc.
• 17.22. Sun Pharmaceutical Industries Limited
• 17.23. Takeda Pharmaceutical Company Limited
• 17.24. Teva Pharmaceutical Industries Limited
• 17.25. Viatris Inc.